International Myeloma Workshop | Conference

Dr. Stadtmauer on Utility of Selinexor in Multiple Myeloma

October 4th 2019

Edward A. Stadtmauer, MD, discusses the use of selinexor in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma

September 20th 2019

Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.

Dr. Chari on Using Selinexor in Multiple Myeloma Treatment

September 20th 2019

Ajai Chari, MD, discusses the use of selinexor in multiple myeloma treatment.

Selinexor Triplet Highly Active in Relapsed Myeloma

September 16th 2019

The all-oral triplet regimen of 60 mg of weekly selinexor plus lenalidomide and dexamethasone appears to be highly active and well-tolerated in patients with relapsed, refractory multiple myeloma, particularly in patients who did not receive prior lenalidomide, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop.

Dr. Richardson on Results of the HORIZON Trial in Relapsed/Refractory Multiple Myeloma

September 16th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses interim results of the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Dr. Mateos on Frail Patients With Multiple Myeloma in the ARROW Trial

September 16th 2019

Maria-Victoria Mateos, MD, PhD, associate professor of medicine, and director of the Myeloma unit at the University Hospital of Salamanca in Spain, discusses the impact of performance status on the outcomes of patients with multiple myeloma in the phase III ARROW trial.

Anti-BCMA BiTE AMG 701 Shows Preclinical Promise in Multiple Myeloma

September 16th 2019

AMG 701, a half-life–extended anti-BCMA bispecific T-cell engager, showed promising in vitro antimyeloma activity and characteristics suitable for once-weekly dosing in patients with multiple myeloma, according to findings presented at the 17th International Myeloma Workshop.

Kumar Discusses Path Forward for Venetoclax in Myeloma

September 16th 2019

Shaji Kumar, MD, discusses the addition of the BCL-2 inhibitor venetoclax to the combination of bortezomib and dexamethasone significantly improved progression-free survival, overall response rate, very good partial response, and minimal residual disease negativity rates in the phase III BELLINI trial in relapsed/refractory patients with multiple myeloma.

Melflufen Regimen Elicits Activity in Relapsed Myeloma With Extramedullary Disease

September 16th 2019

Melflufen and dexamethasone demonstrated encouraging activity in patients with relapsed/refractory multiple myeloma with and without extramedullary disease, with response rates higher than those observed in prior studies of other agents.

Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia

September 15th 2019

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.

x